Scarica l'app Stockscreener
3.69
0.00%
0.00
Pre-mercato:
3.67
-0.02
-0.54%
Precedente Chiudi:
$3.69
Aprire:
$3.73
Volume 24 ore:
3.51M
Relative Volume:
0.93
Capitalizzazione di mercato:
$1.34B
Reddito:
$3.06M
Utile/perdita netta:
$-141.62M
Rapporto P/E:
-5.0184
EPS:
-0.7353
Flusso di cassa netto:
$-78.67M
1 W Prestazione:
-14.98%
1M Prestazione:
+2.22%
6M Prestazione:
-19.08%
1 anno Prestazione:
+137.30%
Intervallo 1D:
$3.595
$3.76
Intervallo di 1 settimana:
$3.465
$4.00
Portata 52W:
$1.15
$6.75
Ataibeckley Inc Stock (ATAI) Company Profile
Nome
Ataibeckley Inc
Settore
Industria
Telefono
49 89 2153 9035
Indirizzo
PROF. J.H. BAVINCKLAAN 7, AMSTELVEEN
Compare ATAI vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATAI
Ataibeckley Inc
|
3.69 | 1.34B | 3.06M | -141.62M | -78.67M | -0.7353 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-20 | Iniziato | Guggenheim | Buy |
| 2025-10-13 | Iniziato | Needham | Buy |
| 2025-07-29 | Iniziato | Oppenheimer | Outperform |
| 2024-11-18 | Reiterato | H.C. Wainwright | Buy |
| 2024-04-03 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-11-01 | Iniziato | Loop Capital | Buy |
| 2021-11-30 | Iniziato | Maxim Group | Buy |
| 2021-11-11 | Iniziato | ROTH Capital | Buy |
| 2021-10-18 | Iniziato | H.C. Wainwright | Buy |
| 2021-09-01 | Iniziato | Jefferies | Buy |
| 2021-07-13 | Iniziato | Berenberg | Buy |
| 2021-07-13 | Iniziato | Canaccord Genuity | Buy |
| 2021-07-13 | Iniziato | Cantor Fitzgerald | Buy |
| 2021-07-13 | Iniziato | Citigroup | Buy |
| 2021-07-13 | Iniziato | Cowen | Outperform |
| 2021-07-13 | Iniziato | Credit Suisse | Outperform |
| 2021-07-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-07-08 | Iniziato | Aegis Capital | Buy |
Mostra tutto
Ataibeckley Inc Borsa (ATAI) Ultime notizie
Is It Time To Reassess AtaiBeckley (ATAI) After Its Recent Share Price Swings? - simplywall.st
Price to sales ratio of AtaiBeckley Inc. – XETR:B72 - TradingView
AtaiBeckley Inc (ATAI)’s Drug Candidate EMP-01 Shows Positive Results in Key Study - Yahoo Finance
ATAI SEC FilingsAtai Beckley Inc 10-K, 10-Q, 8-K Forms - Stock Titan
AtaiBeckley (FRA:B72) PB Ratio : 5.65 (As of Mar. 04, 2026) - GuruFocus
AtaiBeckley (ATAI) to Initiate Phase 3 Depression Study Following Positive FDA Meeting - Insider Monkey
AtaiBeckley Inc (ATAI)'s Drug Candidate EMP-01 Shows Positive Results in Key Study - Finviz
Weighing AtaiBeckley (ATAI) Valuation After Strong One Year Return And Recent Share Price Weakness - Yahoo Finance
AtaiBeckley says aligned with FDA on dual-trial design Phase 3 BPL-003 program - TipRanks
AtaiBeckley's BPL-003: Is It a Breakthrough for BTD or a Risky Investment? - Bitget
AtaiBeckley (FRA:B72) Cyclically Adjusted PS Ratio : (As of Mar. 04, 2026) - GuruFocus
AtaiBeckley (FRA:B72) Shiller PE Ratio : (As of Mar. 03, 2026) - GuruFocus
AtaiBeckley (FRA:B72) Cyclically Adjusted Price-to-FCF : (As of Mar. 03, 2026) - GuruFocus
Why AtaiBeckley (ATAI) Is Down 7.3% After FDA Backs BPL-003 Phase 3 Depression Trials - simplywall.st
ATAI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
AtaiBeckley Inc. Share PriceATAI, RNS News, Articles, Quotes, & Charts (NASDAQ:ATAI) - Proactive Investors
AtaiBeckley reports encouraging Phase 2a data for EMP-01 in social anxiety - Proactive financial news
Berenberg Adjusts AtaiBeckley Price Target to $13 From $12, Maintains Buy Rating - marketscreener.com
AtaiBeckley to Advance BPL-003 Depression Therapy to Late-Stage Program Following US FDA Meeting - marketscreener.com
AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression - Investing News Network
AtaiBeckley cleared for Phase 3 trials of nasal spray depression treatment after FDA backing - Proactive financial news
AtaiBeckley receives FDA support for depression drug trials - Investing.com
Ataibeckley announces successful end-of-phase 2 meeting for BPL-003 in treatment-resistant depression - marketscreener.com
ATAI Stock Receives Buy Rating with Increased Price Target Today - GuruFocus
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Atai Beckley N.V. (ATAI) - The Globe and Mail
AtaiBeckley Inc. (ATAI) Discusses Positive Topline Results From Exploratory Phase IIa Study of EMP-01 in Social Anxiety DisorderSlideshow (NASDAQ:ATAI) 2026-02-28 - Seeking Alpha
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
AtaiBeckley’s MDMA-based drug for anxiety shows benefit in Phase IIa trial - Yahoo
TD Cowen Conference: ATAI, BCRX, BMRN And More To Present Key Updates - RTTNews
AtaiBeckley Inc. (ATAI): Unpacking The 233.90% Potential Upside In The Biotech Sector - DirectorsTalk Interviews
Psychedelic: AtaiBeckley reports EMP-01 met primary objective in Phase 2a trial - TipRanks
AtaiBeckley reports positive Phase 2a trial results for EMP-01 By Investing.com - Investing.com Canada
[144] Atai Beckley N.V. SEC Filing - Stock Titan
AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 in Social Anxiety Disorder - Investing News Network
Small cap wrap: Northstar Gold, AtaiBeckley, Alvopetro Energy, C3 Metals… - Proactive Investors
R-MDMA phase II cheers up Ataibeckley in SAD - BioWorld MedTech
AtaiBeckley stock drops on Phase 2a data; Disc to refile rare disease drug - Endpoints News
Analysts Offer Insights on Healthcare Companies: CareDx (CDNA) and Atai Beckley N.V. (ATAI) - The Globe and Mail
AtaiBeckley reports positive results from Phase 2a social anxiety disorder trial - Proactive Investors
AtaiBeckley's Phase 2a Study Of EMP 01 In Social Anxiety Disorder Meets Key Goal - Nasdaq
AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder - Bitget
AtaiBeckley Shares Rise 2% on Positive Mid-Stage Trial Results - Investing.com India
AtaiBeckley Shares Rise 2% on Positive Mid-Stage Trial Results By Investing.com - Investing.com Nigeria
AtaiBeckley reports positive Phase 2a trial results for EMP-01 - Investing.com
Experimental MDMA pill eases severe social anxiety in early AtaiBeckley trial - Stock Titan
A Look At AtaiBeckley (ATAI) Valuation After Virtual Investor Day Announcement And Strong Recent Returns - simplywall.st
AtaiBeckley’s Contradictory Indicators: Rising Cash Meets Negative Chart Trends - Bitget
JonesTrading Maintains AtaiBeckley(ATAI.US) With Buy Rating, Maintains Target Price $16 - 富途牛牛
AtaiBeckley CFO Change Puts Funding And Dilution In Sharper Focus - simplywall.st
Why AtaiBeckley (ATAI) Is Up 11.2% After CFO Transition And Virtual Investor Day Announcement - Yahoo Finance
Does AtaiBeckley’s (ATAI) CFO Shuffle Reveal a New Financial Strategy for Its Mental Health Pipeline? - simplywall.st
Ataibeckley Inc Azioni (ATAI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
6.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):